1. Home
  2. Development

Tags : Development

PlantForm Signs Research and Development Agreement with Bio-Manguinhos/Fiocruz to Develop Biosimilar Pembrolizumab
Biosimilars

PlantForm Signs Research and Development Agreement with Bio-Manguinhos/Fiocruz to Develop

Tuba Khan April 9, 2021

Shots: The agreement facilitates PlantForm’s collaborations in Brazil to provide affordable, effective cancer drugs to millions of Brazilians The 3yrs. research and development collaboration will culminate in protocols for P-I and P-III clinical trials. The companies will take biosimilar pembrolizumab to world markets, following the completion of clinical trials in Brazil Pembrolizumab is a biosimilar […]Read More

ViewPoints Interview: Adagio Therapeutics’ Tillman Gerngross Shares Insight on the Development of Antibodies to Prevent COVID-19
Viewpoints

ViewPoints Interview: Adagio Therapeutics’ Tillman Gerngross Shares Insight on the

Tuba Khan March 1, 2021

In an interview with PharmaShots, Tillman Gerngross, Ph.D., Co-Founder, and CEO of Adagio Therapeutics shed light on the pre-clinical data of ADG2 and how it works on SARS-CoV-2. Shots: ADG2 showed broad and potent neutralizing activity against SARS-CoV and two SARS-related coronaviruses currently known to be circulating in bat populations (WIV-1 and SHC014) The company […]Read More

UCB Collaborates with Microsoft to Accelerate Drug Discovery and Development
Biotech

UCB Collaborates with Microsoft to Accelerate Drug Discovery and Development

Tuba Khan February 25, 2021

Shots: The collaboration will merge Microsoft’s computational services, cloud and AI with UCB’s drug discovery and development capabilities The companies intend to discover and develop medicines for people living with severe diseases in immunology and neurology. The collaboration follows UCB and Microsoft’s collaboration around COVID-19 Microsoft will provide AI technology and applied scientists to work […]Read More

Evotec Collaborates with Related Sciences for Drug Discovery and Development
Pharma

Evotec Collaborates with Related Sciences for Drug Discovery and Development

Tuba Khan February 11, 2021

Shots: Evotec to receive milestones, royalties, and a founding equity stake in all Related Sciences assets developed under the collaboration Evotec and Related Sciences will jointly discover & develop a multitude of therapeutic approaches with IND filings over a multi-year period. The partnership will combine Related Sciences’ collaborative model and data-driven approach to identify biological […]Read More

Roche Collaborate with Cambridge Quantum Computing to Develop Quantum Algorithm for Drug Discovery and Development
MedTech

Roche Collaborate with Cambridge Quantum Computing to Develop Quantum Algorithm

Tuba Khan January 29, 2021

Shots: CQC collaborates with Roche to design and implement noisy-intermediate-scale-quantum (NISQ) algorithms for early-stage drug discovery and development The collaboration will employ CQC’s quantum chemistry platform ‘EUMEN’, to augment the Roche’s AD research efforts The multi-year collaboration will combine the expertise of both CQC and Roche to advance the application of quantum computing to pharmaceutical […]Read More

Biogen Signs a License Agreement with ViGeneron for Ophthalmic Gene Therapy Development
Biotech

Biogen Signs a License Agreement with ViGeneron for Ophthalmic Gene

Tuba Khan January 5, 2021

Shots: ViGeneron to receive an up front and R&D funding for the mutually agreed workplan and will receive development, regulatory and commercial milestone payments along with royalties on sales of products arising from the collaborations ViGeneron will optimize and validate in vitro therapeutic candidates for undisclosed target to treat inherited eye disease while Biogen has […]Read More

Incyte Collaborates with Cellenkos for CK0804 to Treat Myelofibrosis
Pharma

Incyte Collaborates with Cellenkos for CK0804 to Treat Myelofibrosis

Tuba Khan December 31, 2020

Shots: The companies collaborated to evaluate ruxolitinib in combination with CK0804 in patients with MF and plan to initiate a P-Ib study. Incyte will fund the study while operationalized by Cellenkos Cellenkos to receive $20M as licensing fee, ~$294.5M as development, regulatory and commercialization milestones along with royalties on sales of therapies, if approved. Incyte […]Read More

Zai Lab Signs an Exclusive License Agreement with Cullinan Oncology for the Development and Commercialization of CLN-081 in Greater China
Biotech

Zai Lab Signs an Exclusive License Agreement with Cullinan Oncology

Tuba Khan December 29, 2020

Shots: Cullinan will receive $20M up front and is eligible to receive ~$211M in development, regulatory and sales-based milestone payments Cullinan is also eligible for high-single-digit to low-teen tiered royalties based on sales of CLN-081 in Greater China includes Hong Kong, Macau and Taiwan CLN-081 is an orally available, small-molecule, irreversible EGFR inhibitor, which is […]Read More

Copyright ©2021 PharmaShots | Powered by Octavus Consulting